Annual CFF
$14.59 M
-$70.07 M-82.77%
31 December 2023
Summary:
Sangamo Therapeutics annual cash flow from financing activities is currently $14.59 million, with the most recent change of -$70.07 million (-82.77%) on 31 December 2023. During the last 3 years, it has fallen by -$138.51 million (-90.47%). SGMO annual CFF is now -93.70% below its all-time high of $231.71 million, reached on 31 December 2018.SGMO Cash From Financing Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Quarterly CFF
-$203.00 K
+$330.00 K+61.91%
30 September 2024
Summary:
Sangamo Therapeutics quarterly cash flow from financing activities is currently -$203.00 thousand, with the most recent change of +$330.00 thousand (+61.91%) on 30 September 2024. Over the past year, it has dropped by -$103.00 thousand (-103.00%). SGMO quarterly CFF is now -100.09% below its all-time high of $218.40 million, reached on 30 June 2018.SGMO Quarterly CFF Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
TTM CFF
$21.55 M
-$103.00 K-0.48%
30 September 2024
Summary:
Sangamo Therapeutics TTM cash flow from financing activities is currently $21.55 million, with the most recent change of -$103.00 thousand (-0.48%) on 30 September 2024. Over the past year, it has dropped by -$12.40 million (-36.53%). SGMO TTM CFF is now -91.17% below its all-time high of $244.09 million, reached on 30 June 2018.SGMO TTM CFF Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
SGMO Cash From Financing Performance
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | -82.8% | -103.0% | -36.5% |
| 3 y3 years | -90.5% | -103.7% | -42.8% |
| 5 y5 years | -93.7% | -128.8% | -84.9% |
SGMO Cash From Financing High & Low
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3 years | -90.5% | at low | -100.5% | +87.0% | -77.1% | +47.7% |
| 5 y | 5 years | -93.7% | at low | -100.1% | +87.0% | -87.2% | +47.7% |
| alltime | all time | -93.7% | +7871.6% | -100.1% | +90.5% | -91.2% | +5683.7% |
Sangamo Therapeutics Cash From Financing History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sept 2024 | - | -$203.00 K(-61.9%) | $21.55 M(-0.5%) |
| June 2024 | - | -$533.00 K(-102.4%) | $21.66 M(-24.6%) |
| Mar 2024 | - | $22.12 M(>+9900.0%) | $28.71 M(+96.8%) |
| Dec 2023 | $14.59 M(-82.8%) | $167.00 K(-267.0%) | $14.59 M(-57.0%) |
| Sept 2023 | - | -$100.00 K(-101.5%) | $33.96 M(-56.4%) |
| June 2023 | - | $6.52 M(-18.5%) | $77.87 M(-17.4%) |
| Mar 2023 | - | $8.00 M(-59.0%) | $94.23 M(+11.3%) |
| Dec 2022 | $84.66 M(+157.7%) | $19.54 M(-55.4%) | $84.66 M(+25.9%) |
| Sept 2022 | - | $43.82 M(+91.6%) | $67.24 M(+132.6%) |
| June 2022 | - | $22.87 M(-1559.7%) | $28.91 M(+80.1%) |
| Mar 2022 | - | -$1.57 M(-174.2%) | $16.06 M(-51.1%) |
| Dec 2021 | $32.86 M(-78.5%) | $2.11 M(-61.5%) | $32.86 M(-12.8%) |
| Sept 2021 | - | $5.49 M(-45.2%) | $37.66 M(+11.5%) |
| June 2021 | - | $10.02 M(-34.2%) | $33.79 M(-79.9%) |
| Mar 2021 | - | $15.23 M(+120.2%) | $167.93 M(+9.7%) |
| Dec 2020 | $153.10 M(+7.8%) | $6.92 M(+328.2%) | $153.10 M(+3.9%) |
| Sept 2020 | - | $1.62 M(-98.9%) | $147.40 M(+0.6%) |
| June 2020 | - | $144.16 M(>+9900.0%) | $146.49 M(+3.0%) |
| Mar 2020 | - | $409.00 K(-66.4%) | $142.22 M(+0.1%) |
| Dec 2019 | $142.03 M(-38.7%) | $1.22 M(+73.2%) | $142.03 M(-0.2%) |
| Sept 2019 | - | $704.00 K(-99.5%) | $142.38 M(-0.3%) |
| June 2019 | - | $139.89 M(>+9900.0%) | $142.83 M(-35.5%) |
| Mar 2019 | - | $216.00 K(-86.2%) | $221.34 M(-4.5%) |
| Dec 2018 | $231.71 M(+137.7%) | $1.57 M(+35.1%) | $231.71 M(-4.4%) |
| Sept 2018 | - | $1.16 M(-99.5%) | $242.45 M(-0.7%) |
| June 2018 | - | $218.40 M(+1963.7%) | $244.09 M(+133.3%) |
| Mar 2018 | - | $10.58 M(-14.0%) | $104.63 M(+7.3%) |
| Dec 2017 | $97.49 M(>+9900.0%) | $12.30 M(+338.3%) | $97.49 M(+15.0%) |
| Sept 2017 | - | $2.81 M(-96.4%) | $84.76 M(+2.7%) |
| June 2017 | - | $78.94 M(+2192.0%) | $82.55 M(+2195.6%) |
| Mar 2017 | - | $3.44 M(-914.2%) | $3.60 M(+967.1%) |
| Dec 2016 | $337.00 K(-98.3%) | -$423.00 K(-171.6%) | $337.00 K(-285.2%) |
| Sept 2016 | - | $591.00 K(-3793.8%) | -$182.00 K(-101.2%) |
| June 2016 | - | -$16.00 K(-108.6%) | $14.98 M(-10.4%) |
| Mar 2016 | - | $185.00 K(-119.6%) | $16.72 M(-15.1%) |
| Dec 2015 | $19.71 M(-80.7%) | -$942.00 K(-106.0%) | $19.71 M(+6.5%) |
| Sept 2015 | - | $15.75 M(+812.2%) | $18.51 M(+370.7%) |
| June 2015 | - | $1.73 M(-45.5%) | $3.93 M(-1.1%) |
| Mar 2015 | - | $3.17 M(-247.9%) | $3.98 M(-96.1%) |
| Dec 2014 | $102.18 M(+34.3%) | -$2.14 M(-282.0%) | $102.18 M(-2.5%) |
| Sept 2014 | - | $1.18 M(-33.5%) | $104.80 M(-40.2%) |
| June 2014 | - | $1.77 M(-98.3%) | $175.11 M(-0.1%) |
| Mar 2014 | - | $101.37 M(>+9900.0%) | $175.23 M(+130.2%) |
| Dec 2013 | $76.11 M(+4441.0%) | $480.00 K(-99.3%) | $76.11 M(-0.2%) |
| Sept 2013 | - | $71.49 M(+3682.5%) | $76.26 M(+1336.5%) |
| June 2013 | - | $1.89 M(-15.9%) | $5.31 M(+39.2%) |
| Mar 2013 | - | $2.25 M(+253.9%) | $3.81 M(+127.6%) |
| Dec 2012 | $1.68 M | $635.00 K(+18.2%) | $1.68 M(+33.8%) |
| Sept 2012 | - | $537.00 K(+35.6%) | $1.25 M(+58.6%) |
| June 2012 | - | $396.00 K(+266.7%) | $790.00 K(-98.5%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Mar 2012 | - | $108.00 K(-49.1%) | $51.14 M(-1.4%) |
| Dec 2011 | $51.88 M(+4277.7%) | $212.00 K(+186.5%) | $51.88 M(-0.6%) |
| Sept 2011 | - | $74.00 K(-99.9%) | $52.18 M(+0.2%) |
| June 2011 | - | $50.74 M(+5890.9%) | $52.09 M(+2935.8%) |
| Mar 2011 | - | $847.00 K(+65.4%) | $1.72 M(+44.8%) |
| Dec 2010 | $1.19 M(-95.6%) | $512.00 K(-6500.0%) | $1.19 M(-95.6%) |
| Sept 2010 | - | -$8000.00(-102.2%) | $26.72 M(-1.6%) |
| June 2010 | - | $365.00 K(+15.5%) | $27.17 M(+0.2%) |
| Mar 2010 | - | $316.00 K(-98.8%) | $27.10 M(+1.3%) |
| Dec 2009 | $26.76 M(+1349.0%) | $26.05 M(+5861.1%) | $26.76 M(+2300.3%) |
| Sept 2009 | - | $437.00 K(+45.2%) | $1.11 M(+2.4%) |
| June 2009 | - | $301.00 K(-1304.0%) | $1.09 M(-18.9%) |
| Mar 2009 | - | -$25.00 K(-106.2%) | $1.34 M(-27.3%) |
| Dec 2008 | $1.85 M(-95.6%) | $402.00 K(-2.2%) | $1.85 M(-48.1%) |
| Sept 2008 | - | $411.00 K(-25.9%) | $3.56 M(-91.6%) |
| June 2008 | - | $555.00 K(+15.9%) | $42.63 M(-0.1%) |
| Mar 2008 | - | $479.00 K(-77.4%) | $42.69 M(+1.0%) |
| Dec 2007 | $42.28 M(+102.2%) | $2.12 M(-94.6%) | $42.28 M(+4.1%) |
| Sept 2007 | - | $39.48 M(+6362.0%) | $40.60 M(+3544.2%) |
| June 2007 | - | $611.00 K(+798.5%) | $1.11 M(-94.7%) |
| Mar 2007 | - | $68.00 K(-84.3%) | $20.91 M(+0.0%) |
| Dec 2006 | $20.91 M(+13.7%) | $434.00 K(>+9900.0%) | $20.91 M(-45.7%) |
| Sept 2006 | - | $1000.00(-100.0%) | $38.53 M(-0.2%) |
| June 2006 | - | $20.41 M(>+9900.0%) | $38.61 M(+110.1%) |
| Mar 2006 | - | $65.00 K(-99.6%) | $18.37 M(-0.0%) |
| Dec 2005 | $18.38 M(+3223.5%) | $18.06 M(>+9900.0%) | $18.38 M(+3921.7%) |
| Sept 2005 | - | $78.00 K(-53.6%) | $457.00 K(+14.2%) |
| June 2005 | - | $168.00 K(+136.6%) | $400.00 K(-12.5%) |
| Mar 2005 | - | $71.00 K(-49.3%) | $457.00 K(-17.4%) |
| Dec 2004 | $553.00 K(+143.6%) | $140.00 K(+566.7%) | $553.00 K(+5.7%) |
| Sept 2004 | - | $21.00 K(-90.7%) | $523.00 K(+4.2%) |
| June 2004 | - | $225.00 K(+34.7%) | $502.00 K(+28.1%) |
| Mar 2004 | - | $167.00 K(+51.8%) | $392.00 K(+72.7%) |
| Dec 2003 | $227.00 K(+24.0%) | $110.00 K(>+9900.0%) | $227.00 K(-27.5%) |
| Sept 2003 | - | $0.00(-100.0%) | $313.00 K(+259.8%) |
| June 2003 | - | $115.00 K(+5650.0%) | $87.00 K(-44.9%) |
| Mar 2003 | - | $2000.00(-99.0%) | $158.00 K(-13.7%) |
| Dec 2002 | $183.00 K(-72.4%) | $196.00 K(-186.7%) | $183.00 K(-155.1%) |
| Sept 2002 | - | -$226.00 K(-221.5%) | -$332.00 K(-158.5%) |
| June 2002 | - | $186.00 K(+588.9%) | $568.00 K(+23.2%) |
| Mar 2002 | - | $27.00 K(-108.5%) | $461.00 K(-30.4%) |
| Dec 2001 | $662.00 K(-98.9%) | -$319.00 K(-147.3%) | $662.00 K(+144.3%) |
| Sept 2001 | - | $674.00 K(+753.2%) | $271.00 K(-170.2%) |
| June 2001 | - | $79.00 K(-65.4%) | -$386.00 K(-100.8%) |
| Mar 2001 | - | $228.00 K(-132.1%) | $47.61 M(-22.4%) |
| Dec 2000 | $61.33 M(+728.8%) | -$710.00 K(-4276.5%) | $61.33 M(-1.1%) |
| Sept 2000 | - | $17.00 K(-100.0%) | $62.04 M(+0.0%) |
| June 2000 | - | $48.07 M(+244.6%) | $62.02 M(+344.6%) |
| Mar 2000 | - | $13.95 M | $13.95 M |
| Dec 1999 | $7.40 M | - | - |
FAQ
- What is Sangamo Therapeutics annual cash flow from financing activities?
- What is the all time high annual CFF for Sangamo Therapeutics?
- What is Sangamo Therapeutics annual CFF year-on-year change?
- What is Sangamo Therapeutics quarterly cash flow from financing activities?
- What is the all time high quarterly CFF for Sangamo Therapeutics?
- What is Sangamo Therapeutics quarterly CFF year-on-year change?
- What is Sangamo Therapeutics TTM cash flow from financing activities?
- What is the all time high TTM CFF for Sangamo Therapeutics?
- What is Sangamo Therapeutics TTM CFF year-on-year change?
What is Sangamo Therapeutics annual cash flow from financing activities?
The current annual CFF of SGMO is $14.59 M
What is the all time high annual CFF for Sangamo Therapeutics?
Sangamo Therapeutics all-time high annual cash flow from financing activities is $231.71 M
What is Sangamo Therapeutics annual CFF year-on-year change?
Over the past year, SGMO annual cash flow from financing activities has changed by -$70.07 M (-82.77%)
What is Sangamo Therapeutics quarterly cash flow from financing activities?
The current quarterly CFF of SGMO is -$203.00 K
What is the all time high quarterly CFF for Sangamo Therapeutics?
Sangamo Therapeutics all-time high quarterly cash flow from financing activities is $218.40 M
What is Sangamo Therapeutics quarterly CFF year-on-year change?
Over the past year, SGMO quarterly cash flow from financing activities has changed by -$103.00 K (-103.00%)
What is Sangamo Therapeutics TTM cash flow from financing activities?
The current TTM CFF of SGMO is $21.55 M
What is the all time high TTM CFF for Sangamo Therapeutics?
Sangamo Therapeutics all-time high TTM cash flow from financing activities is $244.09 M
What is Sangamo Therapeutics TTM CFF year-on-year change?
Over the past year, SGMO TTM cash flow from financing activities has changed by -$12.40 M (-36.53%)